RCKT: rocketpharma.com Debt to Equity

The daily price chart for the total debt-to-equity ratio of Rocket Pharmaceuticals (RCKT) is 0.07. The business relies on external contractors for testing and production, focusing instead on research. Its competitive advantage is driven by unique patents in the field of rare blood and heart pathology therapies. The development of new drugs is accelerated through collaboration with academic centers and specialized clinics.

Diversifying the supply of biocomponents for gene therapy ensures operational cycle stability for Rocket Pharmaceuticals (RCKT). Reliable logistics reduce the need for emergency borrowings, which directly impacts the leverage ratio. This coefficient is calculated as the ratio of total liabilities to the company's net assets. It determines the business's degree of dependence on external financing and its solvency risks. By analyzing the company's leverage history, an investor can assess the resilience of the balance sheet.